Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics (Nasdaq: UTHR) announced positive Phase 1 results for miroliverELAP, an external bioengineered liver developed by Miromatrix Medical. In a single-arm safety study, five acute liver failure (ALF) patients who were not transplant candidates were treated continuously for at least 44 hours; the trial met its primary endpoint of survival during treatment and reported no unexpected serious adverse events attributable to the device through 32 days of follow-up. The company will initiate a Phase 2 study and full results will be presented and published in the second half of 2026. miroliverELAP is investigational and not approved for any use.
United Therapeutics (Nasdaq: UTHR) announced the appointment of Kevin J. Tracey, M.D. to its Board of Directors effective January 21, 2026. Dr. Tracey serves as President and CEO of The Feinstein Institutes for Medical Research, Professor of Molecular Medicine and Neurosurgery, and Executive VP, Research at Northwell Health.
He is known for research in inflammation and bioelectronic medicine, discovery of neural circuits controlling immunity, work on monoclonal anti-TNF antibodies, multiple patents, and co-founding biotech companies including SetPoint Medical. United Therapeutics said Dr. Tracey will support its therapeutic pipeline for rare pulmonary diseases and organ manufacturing programs, aligning with the company’s public benefit mission.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, 1:30–2:10 p.m. PST.
Dr. Martine Rothblatt, chairperson and CEO, will deliver the presentation. A live webcast will be available at https://ir.unither.com/events-and-presentations, with an archived recording posted ~24 hours after the session and accessible for 30 days.
United Therapeutics describes itself as the first publicly traded biotech to adopt a public benefit corporation (PBC) structure, focusing on novel therapies and technologies to expand transplantable organs; more information on the PBC is at unither.com/pbc.
United Therapeutics (Nasdaq: UTHR) announced executives will present at two investor conferences in November 2025. Patrick Poisson, EVP Strategic Development, will speak at the UBS Global Healthcare Conference in Palm Beach on Nov 10, 2025, 9:30–10:05 AM ET. James Edgemond, CFO and Treasurer, will speak at the Jefferies Global Healthcare Conference in London on Nov 18, 2025, 12:00–12:25 PM GMT. Both sessions will be available via live webcast on the company investor site and archived recordings will be posted about 24 hours after each session and accessible for 90 days.
United Therapeutics reiterated its mission as a public benefit corporation to develop novel therapies and organ‑availability technologies. The company provided standard forward‑looking statement cautionary language and dated the information Nov 4, 2025.
United Therapeutics (Nasdaq: UTHR) announced the first transplant in its ongoing EXPAND clinical study of the investigational UKidney xenokidney in patients with end-stage renal disease on November 3, 2025. The operation was performed at NYU Langone Health. The UKidney used in the transplant is from a pig with 10 gene edits: six human genes added to improve immunologic compatibility and four porcine genes knocked out to reduce rejection risk and moderate organ growth.
The company described the trial as a first-of-its-kind effort to evaluate xenotransplantation as an alternative to lifelong dialysis, with stated emphasis on patient safety and continued scientific study.
United Therapeutics (Nasdaq: UTHR) reported record third quarter 2025 results with total revenue $799.5M (up 7% YoY) and net income $338.7M (up 10% YoY) for the quarter ended September 30, 2025.
Product highlights: Total Tyvaso sales were $478.0M (+10% YoY) driven by Tyvaso DPI growth; Orenitram sales were $131.1M (+16% YoY). R&D expense rose to $127.5M (+23% YoY).
Capital actions: The company completed accelerated share repurchases totaling about $2.0B aggregate, with ~2.64M shares delivered in Q3 2025 under ASR agreements.
United Therapeutics (Nasdaq: UTHR) will report third quarter 2025 financial results before market open on Wednesday, October 29, 2025. A press release with results will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time on the same day.
The live webcast and a one-year rebroadcast will be available at https://ir.unither.com/events-and-presentations. The company reiterates its public benefit corporation purpose and includes customary forward-looking statement cautionary language dated October 15, 2025.
United Therapeutics (Nasdaq: UTHR) announced it will feature clinical data and sponsor events at the CHEST 2025 Annual Meeting in Chicago, October 19–22, 2025.
Two oral rapid‑fire presentations on Oct 21, 2025: 10:44–10:48 AM CDT — interim PHINDER echocardiographic analysis; 2:03–2:07 PM CDT — impact of inhaled treprostinil initiation timing on hospitalizations in PH‑ILD.
Sponsored events include a fellows breakfast (Oct 18), Women in Chest Medicine luncheon (Oct 20), APP networking event (Oct 20), and a PHinding PH symposium (Oct 20, 6:00–9:00 PM CDT).
United Therapeutics (Nasdaq: UTHR) has announced a webcast to present data from their successful TETON-2 pivotal study of nebulized Tyvaso® for treating idiopathic pulmonary fibrosis (IPF). The presentation will take place on September 28, 2025, at 12:30 p.m. ET.
Dr. Steven D. Nathan, Chair of the TETON Steering Committee, will lead the presentation of data previously shown at the European Respiratory Society Congress. The study successfully met its primary endpoint, demonstrating improvement in absolute forced vital capacity (FVC) compared to placebo, with significant improvements also observed in most secondary endpoints.
United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CEO Martine Rothblatt will participate in a fireside chat at the Bernstein 2nd Annual Healthcare Forum in New York. The presentation is scheduled for September 23, 2025, from 1:10 p.m. to 1:50 p.m. EST.
Investors can access the session through a live webcast on the company's website, with a recorded version available for 90 days after the event. As a unique pharmaceutical company structured as a public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
